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ntiplatelet Therapy
nd Coronary Artery
ypass Graft Surgery
Fallow Land*
illes Montalescot, MD, PHD,
ean-Sébastien Hulot, MD,
ean-Philippe Collet, MD, PHD
aris, France
espite many advances, open heart surgery is still associated
ith the risks of bleeding and thrombotic events. Whether
o continue antiplatelet therapy during surgery is often
andled differently by different institutions, with little in-
erpatient variability within an institution. This confusion is
aused by the lack of scientific evidence, so that decisions are
eing based on individual or local experience, somewhat
riented by recommendations, but based mainly on expert
pinion.
See page 1994
nterruption of antiplatelet therapy (APT). In coronary
atients on single oral APT, discontinuation of APT,
sually aspirin, exposes them to an increased risk of death
1). In stented coronary patients, discontinuation of APT,
specially if done prematurely and/or when interruption
oncerns both antiplatelet agents, exposes them to an
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anofi-Aventis, and Eli Lilly.ncreased risk of stent thrombosis and mortality. Therefore,
urrent guidelines have warned against premature and
njustified discontinuation of APT in coronary patients (2).
In contrast, coronary patients on APT undergoing coro-
ary artery bypass graft (CABG) surgery are exposed to an
xcess of bleeding complications. Bleeding complications
nd transfusions have been associated with an excess of
schemic complications and mortality, at both short- and
ong-term follow-up (3,4). Therefore, current guidelines
ave increased physicians’ awareness of the issue and pro-
osed strategies to reduce the risk of bleeding. Concerning
lopidogrel, it is currently recommended to stop treatment 5
o 7 days before CABG surgery on the basis of pharmaco-
ynamic studies and a post hoc analysis of a large random-
zed trial in acute coronary syndrome (4). Background
spirin therapy is nowadays accepted for CABG surgery,
lthough it was not the case many years ago. Concerns
bout bleeding were such that it resulted in the pre-
perative discontinuation of aspirin therapy until aspirin
as shown to reduce mortality in CABG surgery (5).
Several reports have suggested that the bleeding risk
ould be kept under control during CABG surgery even
ith continuation of dual APT (6,7). Such a strategy would
f course have the advantage of not exposing patients to
ecurrent ischemic events while withholding thienopyridine
reatment and not postponing surgery for the only reason of
ctive APT. Moreover, several reports have suggested in the
ast that APT may improve the post-operative outcome of
atients undergoing CABG surgery. Aspirin prevented
arly post-operative graft occlusion and reduced mortality
5) and glycoprotein IIb/IIIa inhibitors were shown to
educe death or myocardial infarction in CABG patients
hen compared with placebo (8). Platelet consumption and
ysfunction after cardiopulmonary bypass has been widely
escribed with similarities to what was described for hemo-
ialysis. Interestingly, both ticlopidin and clopidogrel have
een shown to reduce the frequency of thrombosis of
rteriovenous fistulae in patients undergoing hemodialysis
9,10). Recently, patients undergoing CABG surgery who
ere taking prasugrel, a thienopyridine more potent than
lopidogrel, had a large excess of major bleeding complica-
ions compared with those taking clopidogrel (11.3% vs.
.6%) in the randomized, double-blind TRITON (TRial to
ssess Improvement in Therapeutic Outcomes by Optimiz-
ng platelet inhibitioN) trial (11). However, mortality rates
fter CABG surgery tended to be lower in the prasugrel-
reated patients than in the clopidogrel-treated patients.
his disconnect between bleeding complications and mor-
ality was further observed in the PLATO (PLATelet
nhibition and Patient Outcomes)-CABG study, which
ound a significant reduction of mortality with ticagrelor, a
tronger P2Y12 antagonist than clopidogrel, whereas bleed-
ng and ischemic event rates were similar with clopidogrel
nd ticagrelor (12). These post hoc analyses have many
iases, and the recommendations in both studies were to
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Antiplatelet Therapy and CABG Surgery December 7, 2010:2003–5ithhold APT for CABG surgery, which was of course
ifficult to control, leaving uncertainty as to the degree of
latelet inhibition or recovery of platelet function at the
ime of surgery. Altogether, the literature on antiplatelet
gents suggests that there may be an ischemic and/or
ortality benefit with some degree of platelet inhibition in
atients undergoing CABG surgery despite a possible risk
f excess bleeding. The optimal degree of platelet inhibition
or the best post-CABG risk/benefit ratio remains entirely
nknown.
ontrolling platelet activity for CABG surgery. Would
nformation on residual platelet activity at the time of CABG
urgery help identify patients at risk of further ischemic or
leeding complications? Is clopidogrel titration possible to
aintain patient platelet reactivity in a predefined “optimal
urgery window?” In this issue of the Journal, Kwak et al. (13)
xplore the relationship between platelet function after clopi-
ogrel discontinuation and periprocedure blood loss. They
orrelated residual platelet reactivity before surgery and blood
oss in 100 patients who interrupted clopidogrel before off-
ump coronary artery bypass graft (OPCABG). The model of
PCABG allows accurate measurements of blood loss and
imits post-operative thrombocytopenia and platelet dysfunc-
ion more frequently seen with cardiopulmonary bypass. They
sed the thromboelastography (TEG) platelet mapping assay
Anemoscope Corp., Niles, Illinois) that measures platelet
ctivation on the basis of blood coagulation and clot strength.
t correlates with bleeding and may be used to guide transfu-
ion after cardiac surgery but is not currently recommended for
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Figure 1 Optimal Window of Platelet Inhibition for PCI or CABG
Is there an optimal window of P2Y12 inhibition for percutaneous coronary intervent
Is the therapeutic window different? *% inhibition with VerifyNow.his indication (4). Limited data suggest that it can also identify
atients at increased risk of ischemic events (14). The authors
ound that a persistent high level of platelet inhibition, as
easured with the TEG platelet mapping assay at the time of
urgery, was associated with a higher volume of blood loss
rrespective of the delay between clopidogrel discontinuation
nd surgery. This finding suggests that recommendations of an
verage delay of discontinuation of APT before surgery (i.e., 5
ays for clopidogrel) is not appropriate at the individual level.
his is in line with what we know of the interindividual
ariability of response to clopidogrel, an inactive pro-drug that
equires hepatic conversion into an active metabolite that binds
o the platelet P2Y12 receptor. The limits of the therapeutic
indow of platelet inhibition are still uncertain for percutane-
us coronary intervention and unknown for CABG (Fig. 1).
What this study does not say is even more important than
hat it does say, and it should stimulate further studies. Is
his test the best tool to identify the potential bleeders
uring or after surgery? Is the cutoff value of 70% obtained with
he TEG platelet mapping assay the ideal threshold for the risk
f bleeding? Is this value the same for on-pump surgery? How
oes it correlate with established point of care assays that have
een used in clinical outcome studies performed in stented
atients? Is there another threshold for the risk of ischemic
vents, and shall we now define an optimal surgery window for
latelet reactivity to operate on patients (Fig. 1)? Can we
mprove the prognosis of CABG patients by a systematic
onitoring of platelet function and operate when they reach
uch a predefined window of platelet reactivity?
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December 7, 2010:2003–5 Antiplatelet Therapy and CABG Surgerycall for studies in CABG patients. Several randomized
rials (NCT00661206, NCT00780156, NCT00977938,
CT00822536, and NCT00640679), totaling 35,000
atients, are evaluating the safety and efficacy of thienopy-
idine interruption after stenting to try to determine the best
iming of discontinuation. Not a single randomized study
as evaluated the safety and efficacy of clopidogrel interrup-
ion before CABG surgery. Despite the huge gap in
nowledge and the lessons learned with aspirin, guidelines
ave validated the concept of clopidogrel interruption and
rovided the timelines for its withdrawal before surgery.
his uncharted territory extends to the post-operative pe-
iod in which similar uncertainties exist about the use of
hienopyridines in patients with or without pre-operative
cute coronary syndromes.
The new tools and the new drugs may help to clarify the
ath to better understanding and better management of
hese patients. The bedside assays to monitor platelet
unction may stimulate descriptive studies on what is cur-
ently performed and what could be new approaches in the
re-operative phase.
Bedside genetic testing is also an interesting way to
redict on-treatment platelet reactivity and off-treatment
esidual platelet inhibition and thus anticipate perioperative
leeding and ischemic events. Although several studies have
ow clearly established the increased risk of ischemic events
n carriers of the loss-of-function CYP2C19*2 genetic
ariant, recent evidence suggests that the gain-of-function
YP2C19*17 genetic variant is associated with an increased
leeding risk in clopidogrel-treated patients (Fig. 1).
hether the delay in clopidogrel discontinuation should be
ndividualized according to the genetic profile requires
urther investigations. Rapid genetic testing is around the
orner and using this information may improve the predict-
bility of platelet function assays.
New drugs, such as cangrelor, an intravenous potent,
eversible, and specific P2Y12 purine receptor antagonist
hat blocks adenosine diphosphate–induced platelet activa-
ion and aggregation, will clarify management of these
atients in the BRIDGE (Maintenance of Platelet Inhibi-
ion With Cangrelor) trial. In this randomized, double-
lind study, patients scheduled for CABG surgery will
eceive from the day of clopidogrel interruption a cangrelor
or placebo) infusion to maintain levels of inhibition at least
quivalent to those expected to be maintained if a thien-
pyridine (clopidogrel or ticlopidine) had not been discon-
inued, using the bedside VerifyNow P2Y12 assay. The
nfusion will be discontinued 1 to 2 h before surgery, with
he aim being to show that patients can undergo surgery
ithout excessive bleeding perioperatively. Other reversible
ntravenous agents are being developed and may well fit the
erioperative management of platelet reactivity in patients
ndergoing CABG surgery, possibly with simultaneous
latelet function monitoring at the bedside.
We need to realize that the risk of bleeding associatedith CABG surgery does not obviate the need for clinical trials
K
tvaluating other hard end points. A series of small studies, such
s the one reported by Kwak et al. (13), could collectively draw
wareness and lead to rigorous exploration of the platelet issues
inked to CABG indication. The new diagnostic tools and the
ew drugs may help to generate concerted scientific action with
nesthetists and cardiac surgeons.
eprint requests and correspondence: Dr. Gilles Montalescot,
ureau 236, Institut de Cardiologie, Hôpital Pitié-Salpêtrière,
7 Boulevard de l’Hôpital, 75013 Paris, France. E-mail: gilles.
ontalescot@psl.aphp.fr.
EFERENCES
1. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or
recent withdrawal of oral antiplatelet agents on acute coronary syn-
dromes. Circulation 2004;110:2361–7.
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the
diagnosis and treatment of non-ST-segment elevation acute coronary
syndromes. Eur Heart J 2007;28:1598–660.
3. Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker
RC. Impact of clopidogrel in patients with acute coronary syndromes
requiring coronary artery bypass surgery: a multicenter analysis. J Am
Coll Cardiol 2008;52:1693–701.
4. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet
and anticoagulation management in cardiac surgery. Eur J Cardiotho-
rac Surg 2008;34:73–92.
5. Mangano DT, Multicenter Study of Perioperative Ischemia Research
Group. Aspirin and mortality from coronary bypass surgery. N Engl
J Med 2002;347:1309–17.
6. Ouattara A, Bouzguenda H, Le Manach Y, et al. Impact of aspirin
with or without clopidogrel on postoperative bleeding and blood
transfusion in coronary surgical patients treated prophylactically with a
low-dose of aprotinin. Eur Heart J 2007;28:1025–32.
7. Shim JK, Choi YS, Oh YJ, Bang SO, Yoo KJ, Kwak YL. Effects of
preoperative aspirin and clopidogrel therapy on perioperative blood
loss and blood transfusion requirements in patients undergoing off-
pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg
2007;134:59–64.
8. Marso SP, Bhatt DL, Roe MT, et al., PURSUIT Investigators.
Enhanced efficacy of eptifibatide administration in patients with acute
coronary syndrome requiring in-hospital coronary artery bypass graft-
ing. Circulation 2000;102:2952–8.
9. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early
failure of arteriovenous fistulas for hemodialysis: a randomized con-
trolled trial. JAMA 2008;299:2164–71.
0. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton
JL. Double-blind randomized trial of the effect of ticlopidine in
arteriovenous fistulas for hemodialysis. Artif Organs 1985;9:61–3.
1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:2001–15.
2. Held C, Bassand JP, Becker RC, et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes undergoing coronary artery
bypass surgery: results from the PLATO trial. Paper presented at:
ACC.10; Atlanta, Georgia; March 14–16, 2010.
3. Kwak Y-L, Kim J-C, Choi Y-S, Yoo K-J, Song Y, Shim J-K.
Clopidogrel responsiveness regardless of the discontinuation date
predicts increased blood loss and transfusion requirement after off-
pump coronary artery bypass graft surgery. J Am Coll Cardiol
2010;56:1994–2002.
4. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel
PA. Increased risk in patients with high platelet aggregation receiving
chronic clopidogrel therapy undergoing percutaneous coronary inter-
vention: is the current antiplatelet therapy adequate? J Am Coll
Cardiol 2007;49:657–66.ey Words: clopidogrel y coronary artery bypass surgery y off-pump y
ransfusion.
